This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Proactive Investors reports on Race Oncology’s revised strategy
Proactive Investors reported on Race Oncology’s revised corporate strategy, designed to maximise the commercial potential of bisantrene. See the full report here.